BIOTECH SQUIRE
About Biotech Squire

Dedicated Partnering Infrastructure for Transatlantic Asset-Centric Biotechs.

Biotech Squire was established around a focused operational premise: early-stage therapeutics teams should not lose institutional clarity—or executive bandwidth—reconciling multi-quarter pharma conversations inside disjointed spreadsheets and email threads.

Transatlantic Stage Alignment

Built for Grant-Funded Teams Through Venture-Backed Early Clinical Programs.

We serve early-stage, asset-centric biotech companies across North America and Europe—from teams advancing non-dilutive translational grants (NIH SBIR/STTR and Horizon Europe / EIC Accelerator) to venture-backed programs moving from pre-IND into early clinical development.

Partnering momentum starts at major conferences—BIO International Convention, BIO-Europe, and J.P. Morgan Healthcare Week—and continues through online portals such as partneringONE and BIO One-on-One Partnering. Our systems preserve continuity from Non-Confidential Outreach through CDA Executed, Data Room & Scientific Diligence, and Term Sheet / Negotiation.

Who We Support

Venture-Backed Biotech Leadership Teams

CEOs and business development leads maintaining structured, audit-ready reporting for an active Board of Directors across quarterly governance cycles.

Pre-Board & Grant-Funded CEOs

Translational founders turning early pharma interactions and conference feedback into an organized, defensible commercial record ahead of institutional Series A diligence.

Operating Principles

Three Standards Governing Every Deployment.

01

Effortless Team-Wide Adoption

Scientific leads, founders, and business development contributors log pharma updates directly inside Outlook or Gmail in seconds—keeping attention on the science and on deal progression rather than on administrative software.

02

Strict Data Hygiene

Automated contact scraping fills pipelines with CROs, patent counsel, and operational vendors. We structure partnering history manually and pair it with a 1-click privacy lock so shared records stay accurate and confidential.

03

Institutional Reporting Standards

Whether updating an active Board of Directors or assembling materials for institutional Series A diligence, external stakeholders expect clear stage definitions, documented pass rationale, and deterministic accountability.

Explicit Scope Boundary

Biotech Squire engineers partnering pipeline infrastructure and operational visibility. We do not evaluate, score, or advise on biology, assays, intellectual property, regulatory filings, or clinical strategy, and we never execute outsourced business development outreach on behalf of clients.

Discretion by Design

Confidentiality, Security & CDA Governance

Mutual CDAs as Standard Practice

Biotech Squire routinely operates under mutual Confidential Disclosure Agreements (CDAs) before any partnering records are handled.

Strict Workspace Access Isolation

Each client operates in an isolated workspace. Access is limited to named leadership and team members you authorize.

No Model Training on Client Data

Client data is never shared with third parties and is never used to train external models.

Institutional-Grade Discretion

Sensitive asset details and counterparty discussions are handled with the discretion expected in pre-IND and early clinical partnering.

Schedule an Introductory Conversation.

Review your partnering visibility requirements and upcoming board or financing milestones.

Book a Call